Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qi-Shen Dan-Shao (QSDS) granules is a Traditional Chinese Medicine (TCM) botanical formulation developed by the Oriental Hospital of the Beijing University of Chinese Medicine. It is formulated based on the 'Yi-Qi Huo-Xue' (Qi-replenishing and blood-activating) therapeutic principle, which aims to resolve blood stasis and improve circulation. The granules are primarily indicated for the treatment of coronary heart disease and angina pectoris, specifically in patients presenting with the TCM pattern of Qi deficiency and blood stasis. QSDS is typically evaluated as an adjunctive therapy alongside standard Western medical treatments (such as antiplatelets and statins) to improve clinical symptoms, cardiac function, and exercise tolerance. The formulation typically contains extracts from several key medicinal herbs, including *Astragalus membranaceus*, *Salvia miltiorrhiza*, and *Paeonia lactiflora*.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Qi-Shen Dan-Shao granules.